Associations - Halaven (eribulin mesylate)

No biomarker	Liposarcoma	No biomarker	Liposarcoma	eribulin mesylate Sensitive: A1 - Approval eribulin mesylate Sensitive : A1	eribulin mesylate Sensitive: A1 - Approval eribulin mesylate Sensitive : A1
No biomarker	Breast Cancer	No biomarker	Breast Cancer	eribulin mesylate Sensitive: A1 - Approval eribulin mesylate Sensitive : A1	eribulin mesylate Sensitive: A1 - Approval eribulin mesylate Sensitive : A1
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2
BRCA2 mutation	Triple Negative Breast Cancer	BRCA2 mutation	Triple Negative Breast Cancer	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2
No biomarker	Leiomyosarcoma	No biomarker	Leiomyosarcoma	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2
No biomarker	Sarcoma	No biomarker	Sarcoma	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	eribulin mesylate Sensitive: B - Late Trials eribulin mesylate Sensitive : B	eribulin mesylate Sensitive: B - Late Trials eribulin mesylate Sensitive : B
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	eribulin mesylate Sensitive: C2 – Inclusion Criteria eribulin mesylate Sensitive : C2	eribulin mesylate Sensitive: C2 – Inclusion Criteria eribulin mesylate Sensitive : C2
PGR expression	Breast Cancer	PGR expression	Breast Cancer	eribulin mesylate Sensitive: C2 – Inclusion Criteria eribulin mesylate Sensitive : C2	eribulin mesylate Sensitive: C2 – Inclusion Criteria eribulin mesylate Sensitive : C2
HER-2 overexpression	Breast Cancer	HER-2 overexpression	Breast Cancer	eribulin mesylate Sensitive: C2 – Inclusion Criteria eribulin mesylate Sensitive : C2	eribulin mesylate Sensitive: C2 – Inclusion Criteria eribulin mesylate Sensitive : C2
TLE3 expression	Triple Negative Breast Cancer	TLE3 expression	Triple Negative Breast Cancer	eribulin mesylate Sensitive: C3 – Early Trials eribulin mesylate Sensitive : C3	eribulin mesylate Sensitive: C3 – Early Trials eribulin mesylate Sensitive : C3
BRCA2 mutation	Triple Negative Breast Cancer	BRCA2 mutation	Triple Negative Breast Cancer	gemcitabine + eribulin mesylate Resistant: C3 – Early Trials gemcitabine + eribulin mesylate Resistant : C3	gemcitabine + eribulin mesylate Resistant: C3 – Early Trials gemcitabine + eribulin mesylate Resistant : C3
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	gemcitabine + eribulin mesylate Resistant: C3 – Early Trials gemcitabine + eribulin mesylate Resistant : C3	gemcitabine + eribulin mesylate Resistant: C3 – Early Trials gemcitabine + eribulin mesylate Resistant : C3
PD-L1 expression	Breast Cancer	PD-L1 expression	Breast Cancer	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr amplification(4)(q22.1)	Leiomyosarcoma	Chr amplification(4)(q22.1)	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr del(3)(q14.2)	Leiomyosarcoma	Chr del(3)(q14.2)	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr del(11)(q25)	Leiomyosarcoma	Chr del(11)(q25)	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr del(2)(q14.1)	Leiomyosarcoma	Chr del(2)(q14.1)	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr del(2)(p12)	Leiomyosarcoma	Chr del(2)(p12)	Leiomyosarcoma	eribulin mesylate Sensitive: C3 – Early Trials eribulin mesylate Sensitive : C3	eribulin mesylate Sensitive: C3 – Early Trials eribulin mesylate Sensitive : C3
Chr del(1)(q44)	Leiomyosarcoma	Chr del(1)(q44)	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr amplification(8)(q13.2)	Leiomyosarcoma	Chr amplification(8)(q13.2)	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr amplification(8)(q22.2)	Leiomyosarcoma	Chr amplification(8)(q22.2)	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr amplification(13)(q13.3)	Leiomyosarcoma	Chr amplification(13)(q13.3)	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr amplification(20)(p12.2)	Leiomyosarcoma	Chr amplification(20)(p12.2)	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr amplification(4)(q26)	Leiomyosarcoma	Chr amplification(4)(q26)	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
ATRX mutation	Leiomyosarcoma	ATRX mutation	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
TP53 mutation	Leiomyosarcoma	TP53 mutation	Leiomyosarcoma	eribulin mesylate Sensitive: C3 – Early Trials eribulin mesylate Sensitive : C3	eribulin mesylate Sensitive: C3 – Early Trials eribulin mesylate Sensitive : C3
PD-L1 expression	Triple Negative Breast Cancer	PD-L1 expression	Triple Negative Breast Cancer	pembrolizumab + eribulin mesylate Sensitive: C3 – Early Trials pembrolizumab + eribulin mesylate Sensitive : C3	pembrolizumab + eribulin mesylate Sensitive: C3 – Early Trials pembrolizumab + eribulin mesylate Sensitive : C3
PIK3CA mutation	Breast Cancer	PIK3CA mutation	Breast Cancer	docetaxel + cyclophosphamide + eribulin mesylate Resistant: C3 – Early Trials docetaxel + cyclophosphamide + eribulin mesylate Resistant : C3	docetaxel + cyclophosphamide + eribulin mesylate Resistant: C3 – Early Trials docetaxel + cyclophosphamide + eribulin mesylate Resistant : C3

Halaven (eribulin mesylate)

Associations
(47)

Associations
(47)

Halaven (eribulin mesylate)

Associations(47)

Associations(47)

Associations
(47)

Associations
(47)